TNFα genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type

Clinical Immunology

Volumn 121, Issue 3, 2006, Pages 305-313

  Castro Santos, Patricia ^a   Mozo, Lourdes ^a   Gutiérrez, Carmen ^a,b   Suárez, Ana ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

ASCA; CARD15; CD; Cytokine polymorphisms; IL 10; Inflammatory bowel disease; PAB; TNF

Indexed keywords

ANTIBODY; AUTOANTIBODY; CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOGLOBULIN A ANTIBODY; INTERLEUKIN 10; PEPTIDOGLYCAN; SACCHAROMYCES CEREVISIAE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARD15 PROTEIN, HUMAN; FUNGUS ANTIBODY; IMMUNOGLOBULIN A;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; EVALUATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOSURVEILLANCE; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; OBSERVATION; PRIORITY JOURNAL; WILD TYPE; ALLELE; BIOSYNTHESIS; BLOOD; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MUTATION; PREVALENCE; SACCHAROMYCES CEREVISIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; CROHN DISEASE; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; INTERLEUKIN-10; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PREVALENCE; SACCHAROMYCES CEREVISIAE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751043841     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.07.006     Document Type: Article

References (56)

1. Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12 (2006) s3
2. Zholudev A., Zurakowski D., Young W., Leitchtner A., and Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 99 (2004) 2235
3. Seibold F., Stich O., Hufnagl R., Kamil S., and M.S. Anti-Saccharomyces cerevisiae antibodies in Inflammatory bowel disease: a family study. Scand. J. Gastroenterol. 36 (2001) 196
4. Strober W., Fuss I., and Blumberg R. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20 (2002) 495
5. Papadakis K., and Targan S. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 5 (2000) 289
6. Bruewer M., Luegering A., Kucharzik T., Parkos C., Madara J., Hopkins A., and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171 (2003) 6164
7. Vermeire S., Peeters M., Vlientick R., Joosens S., Den Hond E., Bulteel V., Bossuyt X., Geypens B., and Rutgeerts P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm. Bowel Dis. 7 (2001) 8
8. Stagg A., Hart A., Kinght S., and Kamm M. The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut 52 (2003) 1522
9. Landers C., Cohavy O., Misra R., Yang H., Lin Y., Braun J., and Targan S. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123 (2002) 689
10. Sendid B., Colombel J., Jacquinot P., Faille C., Fruit J., Cortot A., Lucidarme D., Camus D., and Poulain D. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diagn. Lab. Immunol. 3 (1996) 219
11. McKenzie H., Main J., Pennington C., and Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 31 (1990) 536
12. Murray P., Wang L., Onufryk R., Tepper R., and Young R. T-cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J. Immunol. 158 (1997) 315
13. Wilson A., Symons J., and Mcdowell T. Effects of a polymorphism in the human necrosis factor a promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3195
14. Kroeger K., Steer J., Joyce D., and Abraham L. Effects of stimulus and cell type on the expression of the - 308 tumour necrosis factor promoter polymorphism. Cytokine 12 (2000) 110
15. Suarez A., Castro P., Alonso R., Mozo L., and Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75 (2003) 711
16. Turner D., Williams D., and Sankaran D. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogen. 24 (1997) 1
17. Sashio H., Tamura K., Ito R., Yamamoto Y., Bamba H., Kosaka T., Fukui S., Sawada K., Fukuda Y., Tamura K., and Satomi M. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 53 (2002) 1020
18. Tagore A., Gonsalkorale W., Pravica V., Hajeer A., McMahon R., Whorwell P., Sinnott P., and Hutchinson I. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54 (1999) 386
19. Castro-Santos P., Suarez A., López-Rivas L., Mozo L., and Gutierrez C. TNFa and IL-10 gene polymorphisms in inflammatory bowel disease. Association of - 1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101 (2006) 1
20. Parkes M., and Jewell D. Ulcerative colitis and Crohn's disease: molecular genetics and clinical implications. Expert Rev. Mol. (2001) 1
21. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., Fukase K., Inamura S., Kusumoto S., Hashimoto M., Foster S., Moran A., Fernández-Luna J., and Núñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. J. Biol. Chem. 278 (2003) 5509
22. Girardin S., Boneca I., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D., and Sansonetti P. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278 (2003) 8869
23. Ogura Y., Bonen D., Inohara N., Nicolae D., Chen F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R., Achkar J., Brant S., Bayless T., Kirschner B., Hanauer S., Nuñez G., and Cho J. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603
24. Hugot J., Chamaillard M., Zouali H., Lesage S., Cézard J., Belaiche J., Amer S., Tysk C., O'Morain C., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J., Sahbatou M., and Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599
25. Bonen D., Ogura Y., Nicolae D., Inohara N., Saab L., Tanabe T., Chen F., Foster S., Duerr R., Brant S., Cho J., and Nuñez G. Crohn's disease-associated NOD2 variants share a signalling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124 (2003) 140
26. Hisamatsu T., Suzuki M., Reinecker H., Nadeau W., McCormick B., and Podolsky D. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993
27. Annese V., Lombardi G., Perri F., D'Incà R., Ardizzone S., Riegler G., Giaccari S., Vecchi M., Castiglione F., Gionchetti P., Cocchiara E., Vigneri S., Latiano A., Palmieri O., and Andriulli A. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am. J. Gastroenterol. 100 (2005) 84
28. Brant S., Picco M., Achkar J., Bayless T., Kane S., Brzezinski A., Nouvet F., Bonen D., Karban A., Dassopoulos T., Karaliukas R., Beaty T., Hanauer S., Duerr R., and Cho J. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9 (2003) 281
29. Ahmad T., Armuzzi A., Bunce M., Mulcahy-Hawes K., Marshall S., Orchard T., Crawshaw J., Large O., de Silva A., Cook J., Barnardo M., Cullen S., Welsh K., and Jewell D. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122 (2002) 854
30. Cuthbert A., Fisher S., Mirza M., King K., Hampe J., Croucher P., Mascheretti S., Sanderson J., Forbes A., Mansfield J., Schreiber S., Lewis C., and Mathew C. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122 (2002) 867
31. Abreu M., Taylor K., Lin Y., Hang T., Gaiennie J., Landers C., Vasiliuskas E., Kam L., Rojany M., Papadakis K., Rotter J., Targan S., and Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123 (2002) 679
32. Arnott I., Landers C., Nimmo E., Drummond H., Smith B., Targan S., and Satsangi J. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99 (2004) 2376
33. Vander Cruyssen B., Peeters H., Hoffman I., Laukens D., Coucke P., Marichal D., Cuvelier C., Remaut E., Veys E., Mielants H., De Vos M., and De Keyser F. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin. Exp. Immunol. 140 (2005) 354
34. Lennard-Jones J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol., Suppl. 170 (1989) 2
35. Gasche C., Scholmerich J., Brynskov J., D'Haens G., Hanauer S., Irvine E., Jewell D., Rachmilewitz D., Sachar D., Sandborn W., and Sutherland L. A simple classification of Crohn's disease: Report of the Working Party for World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel. Dis. 6 (2000) 8
36. Stöcker W., Otte J., Ulrich S., Normann D., Finkbeiner H., Stöker K., Jantschek G., and Scriba P. Autoimmunity to pancreatic juice in Crohn's disease. Scand. J. Gastroenterol. 22 (1987) 41
37. Ferreiros-Vidal I., García-Meijide J., Carreira P., Barros F., Carracedo A., Gómez-Reino J., and González A. The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. Rheumatology 42 (2003) 574
38. Crane A., Bradbury L., van Heel D., McGovern D., Brophy S., Rubin L., Siminovitch K., Wordsworth P., Calin A., and Brown M. Role of NOD2 variants in spondyloarthritis. Arthritis Rheum. 46 (2002) 1629
39. Mendoza J., Murillo L., Fernández L., Peña A., Lana R., Urcelay E., Cruz-Santamaría D., de la Concha E., Díaz-Rubio M., and García-Paredes J. Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. Scand. J. Gastroenterol. 38 (2003) 1235
40. Suarez A., Lopez P., Mozo L., and Gutierrez C. Differential effect of IL-10 and TNFa genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann. Rheum. Dis. 64 (2005) 1605
41. Clancy R., Backer C., Yin X., Kapur R., Molad Y., and Buyon J. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block. J. Immunol. 171 (2003) 3253
42. Hirv K., Seyfarth M., Uibo R., Kull K., Salupere R., Latza U., and Rink L. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and DQ alleles and subclinical markers. Scand. J. Gastroenterol. 34 (1999) 1025
43. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S., Landeers C., and Jewell D. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112 (1997) 1845
44. Gottenberg J., Busson M., Loiseau P., Dourche M., Cohen-Solal J., Lepage V., Charron D., Miceli C., Sibilia J., and Maritte X. Association of Transforming Growth Factor b1 and Tumour Necrosis Factor a in patients with primary Sjögren's syndrome. Arthritis Rheum. 50 (2004) 570
45. Barnes R., Allan S., Taylor-Robinson C., Finn R., and Johnson P. Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?. Int. Arch. Allergy Appl. Immunol. 92 (1990) 9
46. Giaffer M., Clark A., and Holdsworth C. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 33 (1992) 1071
47. Stoel M., Jiang H., Van Diemen C., Bun J., Dammers P., Thurnheer M., Kroese F., Cebra J., and Bos N. Restricted IgA repertoire in both B-1 and B-2 cell derived gut plasmablasts. J. Immunol. 174 (2005) 1046
48. Annese V., Andreoli A., Andriulli A., D'Inca R., Gionchetti P., Latiano A., Lombardi G., Piepoli A., Poulain D., Sendid B., and Colombel J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am. J. Gastroenterol. 96 (2001) 2407
49. Kobayashi K., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nuñez G., and Flavell R. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731
50. Halme L., Turunen P., Paavola-Sakki P., Heliö T., Lappalainen M., Färkkilä M., Kontula K., and Repo H. CARD15 frameshift mutation n patients with Crohn disease is associated with immune disregulation. Scand. J. Gastroenterol. 39 (2004) 1243
51. Van der Cruyssen B., Peeters H., Hoffman I., Laukens D., Coucke P., Marichal D., Cuvelier C., Remaut E., Veys E., Mielants H., De Vos M., and De Keyser F. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin. Exp. Immunol. 140 (2005) 354
52. Correa P., Gomez L., Cadena J., and Anaya J. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism. J. Rheumatol. 32 (2005) 219
53. Santos A., Suffys P., Vanderborght P., Moraes M., Vieira L., Cabello P., Bakker A., Matos H., Huizinga T., Ottenhoff T., Sampaio E., and Sarno E. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J. Infect. Dis. 186 (2002) 1687
54. Austin A., Haas K., Naugler S., Bajer A., Garcia-Tapia D., and Estes D. Identification and characterization of a novel regulatory factor IgA-inducing protein. J. Immunol. 171 (2003) 1336
55. Su C., and Lichtenstein G. Are there predictors of Remicade treatment success or failure?. Adv. Drug Deliv. Rev. 57 (2005) 237
56. Balog A., Klausz G., Gal J., Molnar T., Nagy F., Ocsovzky I., Gyulai Z., and Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71 (2004) 274